In today’s session Valeant Pharmaceuticals Intl Inc (VRX) registered an unusually high (264) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the March, 2017 call, expecting serious VRX increase. With 264 contracts traded and 62574 open interest for the Mar, 17 contract, it seems this is a quite bullish bet. The option with symbol: VRX170317C00045000 closed last at: $0.93 or 6.1% down. The stock decreased 2.74% or $0.67 during the last trading session, hitting $23.74. About 12.47M shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 64.81% since March 2, 2016 and is downtrending. It has underperformed by 74.06% the S&P500.
Analysts await Valeant Pharmaceuticals Intl Inc (NYSE:VRX) to report earnings on October, 17. They expect $1.80 EPS, down 33.33% or $0.90 from last year’s $2.7 per share. VRX’s profit will be $610.36 million for 3.30 P/E if the $1.80 EPS becomes a reality. After $1.40 actual EPS reported by Valeant Pharmaceuticals Intl Inc for the previous quarter, Wall Street now forecasts 28.57% EPS growth.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage
Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 9 rate it a “Buy”, 2 “Sell”, while 12 “Hold”. This means 39% are positive. Valeant Pharmaceuticals Intl has been the topic of 73 analyst reports since July 21, 2015 according to StockzIntelligence Inc. On Thursday, December 17 the stock rating was downgraded by Mizuho to “Neutral”. Guggenheim maintained the stock with “Buy” rating in Friday, November 6 report. BMO Capital Markets downgraded the shares of VRX in a report on Thursday, October 22 to “Market Perform” rating. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has “Hold” rating given on Tuesday, October 20 by Deutsche Bank. As per Friday, October 30, the company rating was maintained by UBS. Jefferies maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Monday, November 2. Jefferies has “Buy” rating and $172 price target. The stock has “Sector Perform” rating given by RBC Capital Markets on Wednesday, March 16. Piper Jaffray downgraded Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Tuesday, March 15 to “Underweight” rating. The firm has “Buy” rating given on Wednesday, June 8 by Stifel Nicolaus. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Overweight” rating by Morgan Stanley on Wednesday, August 17.
Insitutional Activity: The institutional sentiment decreased to 0.86 in Q2 2016. Its down 0.06, from 0.92 in 2016Q1. The ratio worsened, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Serv accumulated 0% or 20 shares. Conning last reported 109,769 shares in the company. Millennium Lc last reported 82,670 shares in the company. Scotia Cap has invested 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Academy Cap Mngmt Incorporated Tx last reported 573,321 shares in the company. Trust Of Vermont owns 2,000 shares or 0.01% of their US portfolio. Continental Ltd, a Illinois-based fund reported 95,600 shares. Ladenburg Thalmann Financial Svcs reported 20,226 shares or 0.01% of all its holdings. Amer Int accumulated 0% or 4,200 shares. Jefferies Lc, a New York-based fund reported 62,647 shares. Nebula Cap Mngmt L P has 31,770 shares for 5.07% of their US portfolio. M&R Mgmt has 0.01% invested in the company for 2,530 shares. Delta Lloyd Nv has 0.02% invested in the company for 22,319 shares. Tocqueville Asset Management Lp has 0.01% invested in the company for 51,519 shares. Sg Americas Securities Lc holds 0% or 21,687 shares in its portfolio.
Insider Transactions: Since June 9, 2016, the stock had 2 insider buys, and 0 insider sales for $5.04 million net activity. KARABELAS ARGERIS N had bought 4,000 shares worth $98,600 on Thursday, August 11. Another trade for 202,000 shares valued at $4.94M was made by PAPA JOSEPH C on Thursday, June 9.
Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $8.05 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.